Please note that a publication can be assigned to several endpoints, i.e. the sum of publications from the individual thematic points and subpoints can be greater than the total sum of actual publications.
Authors | Year | Exposed system | Parameters | Magnetic flux density/field strength |
---|---|---|---|---|
Zhang L et al. | 2015 | intact cell/cell culture, CNE-2Z cells (human nasopharyngeal cancer cell line) | static magnetic field | - |
Medeiros HR et al. | 2023 | intact cell/cell culture, SH-SY5Y (human neuroblastoma cell line) | static magnetic field | - |
Guo Z et al. | 2023 | intact cell/cell culture, J1 ESC cells (mouse embryonic stem cells) | static magnetic field | - |
Zafari J et al. | 2024 | intact cell/cell culture, A2780 (human ovarian carcinoma-sensitive to cisplatin) and A2780-CP (human ovarian carcinoma-resistant to cisplatin) | static magnetic field, also other exposures without EMF, co-exposure | - |
Cheng L et al. | 2024 | invertebrate, <i>Caenorhabditis elegans</i> (nematode; different strains) | static magnetic field | - |
Nieminen V et al. | 2025 | intact cell/cell culture, SH-SY5Y cells (human neuroblastoma cell line) | static magnetic field, co-exposure, also other exposures without EMF | - |
Eremenko T et al. | 1997 | intact cell/cell culture, Friend erythroleukemia cell line (clone 745 A) | magnetic field, geomagnetic field, 50/60 Hz, shielding/field deprivation | 0.0025 nT–70 µT |
Volpe P et al. | 2005 | intact cell/cell culture, Friend erythroleukemia cell line | geomagnetic field, 50/60 Hz, shielding/field deprivation | 0.0025 nT–70 µT |
Mo WC et al. | 2013 | intact cell/cell culture, SH-SY5Y (human neuroblastoma cell line) | geomagnetic field, shielding/field deprivation | 200 nT |
Reipert BM et al. | 1996 | intact cell/cell culture, FDCP-mix(A4) cell line (mouse bone marrow cells) | magnetic field, static magnetic field, 50/60 Hz, shielding/field deprivation | 0.2–65 µT |
This website uses cookies to provide you the best browsing experience. By continuing to use this website you accept our use of cookies.